Exeliom

French tech company | Builders Republic

About

Clinical-stage biotech developing microbiome-based therapies from a single strain of the gut commensal bacterium Faecalibacterium prausnitzii — lead candidate in trials for Crohn's disease and as an immuno-oncology combination booster for cancers including gastric, lung and liver tumors.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Extension
Founded
2016
City
PARIS
Region
IDF
Tracked rounds
1
Amount raised
2.9 M€ raised since 2020

Funding rounds

  • Extension — 2025

Investors